Novartis and Array Agree MEK Inhibitor Deal Worth up to USD 467 M
By Debbie Tranter
PharmaDeals Review: Vol 2010 Issue 5 (Table of Contents)
Published: 24 May-2010
DOI: 10.3833/pdr.v2010i5.1330 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Novartis has agreed to pay Array BioPharma USD 467 M for worldwide rights to those MEK inhibitors in clinical development, thus strengthening its involvement in the cancer therapeutics arena...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login on the top right purple box.
Copyright: PharmaVentures Ltd
RSS